The Latest
AI: Digital to Physical | BEYOND Expo 2026 Leads Transformative Global Direction of Tech

AI: Digital to Physical | BEYOND Expo 2026 Leads Transformative Global Direction of Tech

MACAO, May 31, 2026 /PRNewswire/ — The BEYOND Expo 2026 has shown what…
  • May 31, 2026
Golden Goblet Competition Lineup Announced: Spotlight on the 2026 Contenders

Golden Goblet Competition Lineup Announced: Spotlight on the 2026 Contenders

SHANGHAI, May 31, 2026 /PRNewswire/ — The 28th Shanghai International Film Festival…
  • May 31, 2026

Dizal Presents Positive NSCLC Data for Fourth-Generation EGFR TKI DZD6008 and Golidocitinib in Combination with Anti-PD-1 at ASCO 2026

Oral presentation of DZD6008 demonstrated strong and durable anti-tumor activity, excellent BBB-penetrant…
  • May 31, 2026
Sacituzumab Tirumotecan (sac-TMT) in Combination with Pembrolizumab for First-Line Treatment of PD-L1-Positive NSCLC Published in The Lancet

Sacituzumab Tirumotecan (sac-TMT) in Combination with Pembrolizumab for First-Line Treatment of PD-L1-Positive NSCLC Published in The Lancet

CHENGDU, China, May 31, 2026 /PRNewswire/ — Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (the…
  • May 31, 2026

Cyient Enters Agreement to Acquire TAO Digital

Acquisition enhances Cyient’s offering portfolio with AI-native data and lifecycle engineering capabilities…
  • May 31, 2026
THE KILLERS ROCK THE UEFA CHAMPIONS LEAGUE FINAL KICK OFF SHOW PRESENTED BY PEPSI®

THE KILLERS ROCK THE UEFA CHAMPIONS LEAGUE FINAL KICK OFF SHOW PRESENTED BY PEPSI®

Millions of fans from across the world tuned in to watch the…
  • May 31, 2026
The Results of Phase III OptiTROP-Lung05 Study of Sacituzumab Tirumotecan (sac-TMT) Presented as an ASCO Oral Presentation and Simultaneously Published in The Lancet

The Results of Phase III OptiTROP-Lung05 Study of Sacituzumab Tirumotecan (sac-TMT) Presented as an ASCO Oral Presentation and Simultaneously Published in The Lancet

CHENGDU, China, May 30, 2026 /PRNewswire/ — Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.…
  • May 30, 2026
Kelun-Biotech Presents Pivotal Phase II Data for Lunbotinib Fumarate (A400/EP0031) in RET Fusion-Positive NSCLC at 2026 ASCO

Kelun-Biotech Presents Pivotal Phase II Data for Lunbotinib Fumarate (A400/EP0031) in RET Fusion-Positive NSCLC at 2026 ASCO

CHENGDU, China, May 30, 2026 /PRNewswire/ — Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.…
  • May 30, 2026